{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(1)"],"submitter":["Fruchart JC"],"pubmed_abstract":["In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent re"],"journal":["Cardiovascular diabetology"],"pagination":["71"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6549355"],"repository":["biostudies-literature"],"pubmed_title":["The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation."],"pmcid":["PMC6549355"],"pubmed_authors":["Wahli W","Vrablik M","Sadikot S","Ogawa H","Santos RD","Hermans MP","Lorenzatti AJ","Su TC","Corsini A","Eckel RH","Nordestgaard BG","Ceska R","Tartar A","Ezhov MV","Aguilar-Salinas C","Krempf M","Pradhan A","Zambon A","Tenenbaum A","Aikawa M","Despres JP","Ponte-Negretti CI","Susekov AV","Taskinen MR","Kodama T","Sritara P","Amarenco P","Libby P","Farnier M","Al Rasadi K","Barter PJ","Reiner Z","Plutzky J","Lim S","Duriez P","Tomlinson B","Ruscica M","Stock JK","Ginsberg HN","Ray KK","Tybjærg-Hansen A","Ishibashi S","McPherson R","Watts GF","Ridker PM","Karpe F","Fruchart JC","Koenig W","Packard CJ","Tokgozoglu LS","Shimano H","Yokote K","Yamashita S","Valensi P","Nunez-Cortes JM"],"additional_accession":[]},"is_claimable":false,"name":"The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.","description":"In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent re","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jun","modification":"2026-06-19T03:17:25.777Z","creation":"2019-07-24T07:10:06Z"},"accession":"S-EPMC6549355","cross_references":{"pubmed":["31164165"],"doi":["10.1186/s12933-019-0864-7"]}}